Healthcare
uniQure N.V.(QURE)
Live Price
Offline$46.29
-3.88% today
1Y Change
+245.23%
Window
Jun 23, 2025 โ Jun 17, 2026
- Market Cap
- $1.18B
- Revenue Growth
- -40.6%
- EPS Growth
- +29.7%
- Dividend Yield
- 0.0%
Coverage: 248 bars ยท Jun 23, 2025 โ Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
uniQure N.V. (QURE) is a Healthcare stock with a market cap of $1.18B and listed on NASDAQ. The stock last traded around $46.29 and up 245.2% across the available one-year price window (Jun 23, 2025 โ Jun 17, 2026). Baseline metrics include revenue growth of -40.6%, EPS growth of +29.7%, a dividend yield of 0.0%. What stands out right now is revenue -40.6%, EPS +29.7%, free cash flow +4.4% with operating margin -1157.9% and ROIC -24.3%. Valuation already assumes a fairly strong business story at price/sales 73.2. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines QURE price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-40.6% vs +7.6% peer median
Operating Margin
Below sector median
-1157.9% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 8, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -40.6% and EPS is at +29.7%, with operating margin around -1157.9%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +28.4% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 8, 2026 | โ | -0.1% | -2.2% | -2.4% |
2026 Mar 2, 2026 | +39.8% | -14.0% | +71.3% | +40.3% |
2025 Nov 10, 2025 | -62.4% | +17.9% | +16.0% | -20.5% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
QURE
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
QURE Max Drawdown
-87.21%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for QURE and SPY.
Company Overview
uniQure N.V.
NASDAQ Global Select
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
- Leadership
- Matthew Craig Kapusta
- IPO Date
- Feb 5, 2014
- Employees
- 209
- Street Address
- Paasheuvelweg 25a
- Mailing
- Amsterdam, 1105 BP
- Region
- Amsterdam, NL
- Reporting Currency
- USD
- Investor Line
- 31 20 240 6000
- Last Updated
- May 4, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 73.2
- Price/Book
- 5.5
Growth
- Revenue
- -40.6%
- EPS
- +29.7%
- Free Cash Flow
- +4.4%
Profitability
- Gross Margin
- 71.1%
- Operating Margin
- -1157.9%
- Net Margin
- -1236.0%
- ROE
- -174.0%
- ROIC
- -24.3%
Balance Sheet
- Debt/Equity
- 2.70
- Current Ratio
- 10.43
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.